DK0918523T3 - Behandling af arthritiske lidelser, rheumatoid arthritis og manifestationer associeret med rheumatoide lidelser - Google Patents
Behandling af arthritiske lidelser, rheumatoid arthritis og manifestationer associeret med rheumatoide lidelserInfo
- Publication number
- DK0918523T3 DK0918523T3 DK97906339T DK97906339T DK0918523T3 DK 0918523 T3 DK0918523 T3 DK 0918523T3 DK 97906339 T DK97906339 T DK 97906339T DK 97906339 T DK97906339 T DK 97906339T DK 0918523 T3 DK0918523 T3 DK 0918523T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- rheumatoid
- treatment
- syndrome
- manifestations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS4325 | 1996-02-19 | ||
GBGB9606736.8A GB9606736D0 (en) | 1996-02-19 | 1996-03-29 | Therapeutic method |
PCT/IS1997/000001 WO1997029750A1 (fr) | 1996-02-19 | 1997-02-19 | Traitement des affections arthritiques, de la polyarthrite rhumatoide et des manifestations associees aux affections rhumatoides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0918523T3 true DK0918523T3 (da) | 2003-05-26 |
Family
ID=36764777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97906339T DK0918523T3 (da) | 1996-02-19 | 1997-02-19 | Behandling af arthritiske lidelser, rheumatoid arthritis og manifestationer associeret med rheumatoide lidelser |
Country Status (11)
Country | Link |
---|---|
US (1) | US6358941B1 (fr) |
EP (1) | EP0918523B1 (fr) |
AT (1) | ATE232102T1 (fr) |
AU (1) | AU2105997A (fr) |
CA (1) | CA2251114C (fr) |
DE (1) | DE69718915T2 (fr) |
DK (1) | DK0918523T3 (fr) |
ES (1) | ES2192667T3 (fr) |
GB (1) | GB9606736D0 (fr) |
HK (1) | HK1020535A1 (fr) |
WO (1) | WO1997029750A1 (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8742198A (en) * | 1997-08-15 | 1999-03-08 | Shire International Licensing B.V. | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
IT1304904B1 (it) * | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
US20030224071A1 (en) * | 1999-08-20 | 2003-12-04 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
CA2310950C (fr) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | Posologie de galantamine efficace qui reduit les effets secondaires |
US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
CA2447619A1 (fr) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Composition accelerant la guerison d'une fracture osseuse |
MXPA03010672A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Composicion para el tratamiento regenerativo de enfermedades del cartilago. |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US20050048543A1 (en) * | 2003-07-11 | 2005-03-03 | Jeroen Aerssens | CHRNA2 genetic markers associated with galantamine response |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
WO2005042762A2 (fr) * | 2003-10-28 | 2005-05-12 | Genaissance Pharmaceuticals, Inc. | Marqueurs genetiques lrpap1 associes a la reponse a la galantamine |
US7250258B2 (en) * | 2003-12-15 | 2007-07-31 | Pgxhealth Llc | CDK5 genetic markers associated with galantamine response |
WO2005065662A1 (fr) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Formulations solides d'administration de galantamine |
CA2551946A1 (fr) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Formulations de galantamine |
ES2471403T3 (es) * | 2004-04-20 | 2014-06-26 | Sphingotec Gmbh | Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico m�dico |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
US7888346B2 (en) * | 2004-09-24 | 2011-02-15 | Universtiy of Maryland, Baltimore | Method of treating organophosphorous poisoning |
EP2008660A1 (fr) | 2004-10-12 | 2008-12-31 | Ernir Snorrason | Procédé de traitement de maladies de la peau |
CA2609612C (fr) | 2005-05-23 | 2014-09-23 | President & Fellows Of Harvard College | Utilisation d'huperzine pour traiter l'epilepsie |
CN101190330A (zh) * | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
FR2912841B1 (fr) * | 2007-02-15 | 2009-05-22 | Soitec Silicon On Insulator | Procede de polissage d'heterostructures |
US20090324585A1 (en) * | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
US20110224245A1 (en) * | 2008-09-04 | 2011-09-15 | President And Fellows Of Harvard College | Treatment Of Neurological Disorders Using Huperzine |
ES2396300T3 (es) | 2008-11-19 | 2013-02-20 | Envivo Pharmaceuticals, Inc. | Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma |
CN102573848A (zh) * | 2009-04-24 | 2012-07-11 | 济州大学校产学协力团 | 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物 |
CN102802620A (zh) * | 2009-05-11 | 2012-11-28 | 英维沃医药有限公司 | 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍 |
US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
US20110212928A1 (en) | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
WO2011146511A1 (fr) | 2010-05-17 | 2011-11-24 | Envivo Pharmaceuticals, Inc. | Forme cristalline de monohydrate d'hydrochlorure de (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide |
WO2011151359A1 (fr) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione |
EP2640378A4 (fr) * | 2010-11-18 | 2014-05-21 | Envivo Pharmaceuticals Inc | Traitement d'inflammation avec certains agonistes des récepteurs alpha-7 de l'acide nicotinique en combinaison avec inhibiteurs d'acétylcholinestérase |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
EP2919788A4 (fr) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | Méthodes et compositions pour le traitement de la schizophrénie |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
ES2881081T3 (es) | 2013-03-15 | 2021-11-26 | Agenebio Inc | Procedimientos y composiciones para mejorar la función cognitiva |
EP3265127B1 (fr) | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone et octreotide pour le traitement du syndrome de cushing chez un patient ayant une tumeur neuroendocrine pancréatique sécrétant l'hormone adrénocorticotrope (acth) |
JP6899043B2 (ja) | 2015-05-22 | 2021-07-07 | エージンバイオ, インコーポレイテッド | レベチラセタムの持続放出性医薬組成物 |
JP2020510011A (ja) | 2017-03-09 | 2020-04-02 | コーセプト セラピューティクス, インコーポレイテッド | カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 |
CN109200051A (zh) * | 2017-07-03 | 2019-01-15 | 南京和博生物医药有限公司 | 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途 |
WO2023070351A1 (fr) * | 2021-10-27 | 2023-05-04 | 香港理工大学 | Prévention et traitement de maladies ostéoarticulaires par inhibition de l'acétylcholinestérase |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US661509A (en) * | 1900-09-04 | 1900-11-13 | John S Fogg | Traveler's hat-conformer. |
US5360811A (en) | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
WO1992020327A1 (fr) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase |
-
1996
- 1996-03-29 GB GBGB9606736.8A patent/GB9606736D0/en active Pending
-
1997
- 1997-02-19 CA CA002251114A patent/CA2251114C/fr not_active Expired - Fee Related
- 1997-02-19 AT AT97906339T patent/ATE232102T1/de not_active IP Right Cessation
- 1997-02-19 DE DE69718915T patent/DE69718915T2/de not_active Expired - Fee Related
- 1997-02-19 WO PCT/IS1997/000001 patent/WO1997029750A1/fr active IP Right Grant
- 1997-02-19 US US09/125,306 patent/US6358941B1/en not_active Expired - Fee Related
- 1997-02-19 AU AU21059/97A patent/AU2105997A/en not_active Abandoned
- 1997-02-19 ES ES97906339T patent/ES2192667T3/es not_active Expired - Lifetime
- 1997-02-19 DK DK97906339T patent/DK0918523T3/da active
- 1997-02-19 EP EP97906339A patent/EP0918523B1/fr not_active Expired - Lifetime
-
1999
- 1999-12-02 HK HK99105614A patent/HK1020535A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2251114C (fr) | 2007-10-02 |
DE69718915D1 (de) | 2003-03-13 |
GB9606736D0 (en) | 1996-06-05 |
EP0918523B1 (fr) | 2003-02-05 |
US6358941B1 (en) | 2002-03-19 |
ES2192667T3 (es) | 2003-10-16 |
EP0918523A1 (fr) | 1999-06-02 |
ATE232102T1 (de) | 2003-02-15 |
HK1020535A1 (en) | 2000-05-12 |
DE69718915T2 (de) | 2003-12-11 |
WO1997029750A1 (fr) | 1997-08-21 |
CA2251114A1 (fr) | 1997-08-21 |
AU2105997A (en) | 1997-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0918523T3 (da) | Behandling af arthritiske lidelser, rheumatoid arthritis og manifestationer associeret med rheumatoide lidelser | |
MD809C2 (ro) | (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii | |
RO116342B1 (ro) | Compoziţie farmaceutică lichidă, orală | |
TR200001982T2 (tr) | Farmasötik vurulu salınımlı oral dozaj şekli. | |
UA72881C2 (uk) | Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука | |
BG103190A (en) | Substituted pyrimidine derivatives and their pharmaceutical application | |
DK1126828T3 (da) | Oral indgivelse af adenosin-analoger | |
LU90987I2 (fr) | Copaxone et ses dérivés pharmaceutiquement acceptables | |
BR0008059A (pt) | Composições de valdecoxib | |
MX163955B (es) | Composicion farmaceutica de dihidrocodeina e ibuprofen | |
MD1838G2 (ro) | Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice | |
JP2002523370A5 (fr) | ||
PT921787E (pt) | Regime de administracao de inibidores de atpase de h',k' | |
DK446684D0 (da) | Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme | |
GR3019782T3 (en) | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents | |
MY104061A (en) | Pharmaceutically useful polymorphic modification of buspirone | |
DK1007040T3 (da) | Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom | |
DE69128254D1 (de) | Antihypertensive benzopyran-derivate | |
FI932490A0 (fi) | Underenhetsvaccin mot Neisseria meningitidis-infektioner och motsvarande underenheter i rent tillstaond | |
BG103435A (en) | Lamivudin- and zidovudin-containing pharmaceutical compositions | |
ZA979338B (en) | Peptide compounds. | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
FR2704857B1 (fr) | Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant. | |
FR2612519B1 (fr) | Nouvelles fractions peptidiques inductrices d'anticorps protecteurs contre le virus de la leucemie bovine, procede pour l'obtention de telles fractions, leurs sequences codantes et vaccins realises a partir de ces fractions | |
ZW6789A1 (en) | &-adrenergic receptor antagonists |